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Abstract
Expression of the Gala Gal epitope on membrane glycolipids and glycoproteins is known to vary widely from one1,3
tissue to another. In the course of studying the mechanisms underlying this variability, we have isolated from pig cDNA
 .four sequences corresponding to four isoforms of a -galactosyltransferase a GT , the Golgi enzyme that links galactose1,3 1,3
in a on the galactose residue of N-acetyllactosamine. The isoforms differ from each other in the alternative presence of1,3
two nucleotide stretches of 36 and 63 base pairs in a segment encoding the stem region of the protein. Stable expression
experiments show that all four isoenzymes can confer a-galactosyltransferase activity to HeLa cells, and that they are all
located within the Golgi compartment, indicating that variations in length in the stem region do not affect enzyme activity
or cellular localization. Analysis of RNA from different pig organs and cells shows quantitative differences between tissues
in levels of a GT, as well as qualitative differences, the four isoforms being unequally represented in different tissues.1,3
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1. Introduction
Carbohydrate epitopes in cell membrane proteins
and lipids constitute a major proportion of the surface
antigens displayed by animal cells. The type and
abundance of such molecules vary between different
w xspecies and tissues 1 . One noteworthy discrepancy
is the absence of the Gala Gal epitope in humans,1,3
apes, and Old World monkeys, resulting from
Abbreviations: a GT, UDP-Gal:Galb 1-4GlcNAc a -1,3 1,3
galactosyltransferase; bp, base pairs; PCR, polymerase chain
reaction; PAEC, porcine aortic endothelial cell; FITC, fluorescein
isothiocyanate.
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frameshift and nonsense mutations in the UDP-
Gal:Gal b 1-4GlcNAc a -galactosyltransferase1,3
 .a GT gene and lack of mRNA production in this1,3
w xphylum 2 . This mutation occurred less than 28
million years ago after the divergence of apes from
w xmonkeys 3,4 . a GT is a terminal glycosyltrans-1,3
ferase widely expressed in all other mammalian
species studied so far. It catalyses the transfer of
galactose in a configuration upon the galactose of1,3
N-acetyllactosamine substrates present in membrane
glycolipids and glycoproteins. The enzyme differs
from blood group B-specific galactosyltransferase in
 .that the sequence a-L-Fuc 1,2 -b-D-GlcNAc is not
an acceptor. Glycosyltransferases have been localized
w xin the trans cisternae and trans Golgi network 5,6 .
They are type II proteins that share common struc-
tural features including a single hydrophobic trans-
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membrane region, close to the amino terminus, that
serves as a non-cleavable signal anchor sequence. It
links a short cytoplasmic amino-terminal tail to an
intra-Golgi stem region. The latter is a flexible, ac-
cessible segment, devoid of secondary structure,
which anchors a large carboxyterminal catalytic do-
main. Glycosyltransferases appear to be localized to
the Golgi apparatus largely due to the presence of
specific anchoring residues in the membrane-span-
w xning domain 7 , although some glycosyltransferases
may also be partly retained in the Golgi by residues
in the stem region flanking the transmembrane do-
w xmain 8,9 .
Several glycosyltransferase genes give rise to mul-
tiple protein isoforms. These isoforms have been
ascribed in different reports to multiple transcrip-
w xtional start sites 10,11 , alternative exon splicing
w x w x12,13 , and post-translational modifications 14,15 .
In the case of a GT in mice, transcripts for multiple1,3
protein isoforms are produced from a single genomic
locus as a result of alternative splicing of exons 5 and
6, leading to the synthesis of four proteins with
w xvariations in the length of their stem regions 12 .
Whether the different a GT protein isoforms are1,3
expressed at equivalent levels, and whether their
differences in size confer different enzymatic proper-
ties or different cellular localization, is unknown.
Research into the expression of a GT in the pig1,3
has recently been boosted by the growing interest in
pig-to-man xenotransplantation, a situation in which
a-galactosyl residues exposed on pig endothelium
 .due to a GT activity in this species trigger hyper-1,3
acute rejection as a consequence of the binding of
 .natural anti-Gala Gal anti-Gal antibodies present1,3
in human serum, which elicitate complement activa-
w xtion and ADCC 16,17 . In order to investigate the
expression of a GT in pig organs and endothelial1,3
cells, we used PCR amplification to isolate fragments
of variable size corresponding to four transcripts
which show alternative nucleotide fragments of 36
and 63 base pairs, spanning the entire stem region of
the protein. Using human cells stably transfected with
Flag-tagged a GT constructs containing the four1,3
transcripts, we determined that the four isoproteins
conserve their a GT activity and are similarly local-
ized in the Golgi apparatus. To elucidate the relative
expression of the different porcine a GT isoforms,1,3
we analyzed their transcripts in pig tissues. Quantita-
tive as well as qualitative differences were observed.
In xenotransplantation, donor endothelial cells are
activated by recipient monocytes producing TNFa
w x18 , and the Gala Gal structure is the major xe-1,3
noepitope recognized by human anti-pig antibodies;
we therefore also looked for modifications in tran-
scripts for a GT in endothelial cells during TNFa1,3
activation. We show that this enzyme’s steady state
mRNA level is mildly up-regulated in EC upon TNFa
activation.
2. Experimental procedures
2.1. Tissues and cells
 .Organs from large pigs 200–300 kg were ob-
tained from a local slaughterhouse. Enzymatic isola-
tion and culture of porcine aortic endothelial cells
 . w xPAEC was performed as described previously 19 .
PAEC were stimulated with 100 Urml human TNFa
 .Genzyme, Cambridge, MA, USA with or without
10 mgrml of cycloheximide.
2.2. Oligonucleotides
The following oligonucleotides were synthesized
 . Xby GenSet Paris, France : oligonucleotide 1, 5 -AG-
GAAGAGTGGTTCTGTC-3X corresponding to nu-
cleotides 12–30 of clone a GTiso1; oligonucleotide
2, 5X-GTTATGGTCACGACCTCT-3X corresponding
to nucleotides 324–306 of clone a GTiso1; oligo-
nucleotide 3, 5X-TATAGAATTCGAAAATAATG-
AATGTCAAAGGAAGAGTGGTTCTGTC-3X corre-
sponding to an EcoRI site in front of nucleotides
y7–29 of clone a GTiso1; oligonucleotide 4, 5X-AT-
ATAACTAGTGGAAGCTCTCCTCTGTTG-3X cor-
responding to nucleotides 266–254 with a G to A261
mutation introduced into the third base of a proline
codon; oligonucleotide 5, 5X-ATATACTAGTGGAC-
TGGTTTAATC-3X corresponding to nucleotides
266–284 and with the same G to A mutation as in261
oligonucleotide no. 4; oligonucleotide 6, 5X-CTCG-
AGTCACTTGTCATCGTCGTCCTTGTAATCGAT-
GTTATTTCTAACCAAATT-3X corresponding to nu-
cleotides 1092–1113 with an oligonucleotide coding
 .for a FLAG peptide Kodak, New Haven, CT, USA ,
a stop codon and a XhoI site added in frame.
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2.3. Cloning and construction of epitope-tagged pig
a GT isoforms
 .A 2 kb a GT cDNA clone pCDNA-a GT was1,3
isolated from a cDNA library constructed in the
 .pCDNA-1 vector Invitrogen, Leek, The Netherlands ,
by transfer hybridization using a PCR probe ampli-
fied with primers 1 and 2 derived from the sequence
w x.published by 20 . This clone is referred to here as
isoform no. 2. Porcine a GT isoforms 1, 3, and 41,3
were isolated by PCR amplification of a region span-
ning exons 4–7 with primers 1 and 2, using retro-
transcribed RNA from resting PAEC. Amplified frag-
ments were blunted with Kleenow polymerase and
cloned into the SmaI site of the pUC18 plasmid.
Three clones containing fragments of 300, 237, and
201 bp were obtained and used as a template to
X  .introduce an EcoRI site at the 5 -end with oligo 3
 .and a SpeI site into exon 7 with oligo 4 by means
of secondary PCR amplification. The introduction of
this SpeI site does not modify the amino acid se-
quence. PCR products were ligated into an EcoRI-
SpeI digested pKS plasmid. The remaining 3X part of
the coding sequence was PCR amplified from the
pCDNA-a GT clone with primers 5 and 6, blunted
and cloned into the EcoRV site of a pKS plasmid.
From this plasmid, selected for correct orientation of
the insert, a SpeI fragment bearing the coding region
from nucleotide 262 to 1125, in frame with a FLAG
 .sequence contained in oligonucleotide 6 , was iso-
lated and cloned into the SpeI sites of the pKS
plasmids containing the variable 5X regions. The re-
sulting constructs were proofread by sequencing, and
EcoRI fragments containing the entire coding se-
quences were subcloned in the CMV-based eucary-
otic expression vector pCDAAS-neo Dr. de Martin,
.Vienna . Flagged porcine a GT isoform 2 was iso-
lated in the same way, using the pCDNA-a GT clone
as the initial template.
2.4. Cell transfections
Sub-confluent HeLa cells grown in RPMI-10%
FCS were trypsinized, resuspended at 5P106 cellsrml
in ice-cold medium and mixed with 20 mgrml of
plasmid DNA bearing the transgene and a neomycin
resistance gene. Cells were electroporated at 250 V,
350 mF, left on ice for 10 min. and seeded at 2000
cellsrcm2. After 24 h, 500 mgrml G418 was added
and cells were cultured for two weeks. Clones were
isolated and expanded in the presence of G418.
2.5. Immunofluorescence
For the expression of a-galactosyl epitopes on cell
membranes, clones of HeLa cells expressing one of
the four a GT isoforms were seeded in 4-well1,3
microscope chamber slides Nunc, Roskilde, Den-
.mark . Two days after seeding, cells were washed
twice with PBS, fixed for 10 min at room tempera-
ture with 3% paraformaldehyde, washed again and
incubated for 1 h at room temperature with FITC-iso-
lectin B4 from Banderaea simplicifolia Sigma, St.
.Louis, MO, USA , 1:100 dilution in PBS. Slides were
then washed 4 times in PBS before mounting. For
subcellular localization, cells were fixed with 3%
paraformaldehyde and permeabilized by three se-
quential 5 min. incubations with 50%, 100%, and
50% ice-cold acetone. After three washings with
PBSr0.5% Tween-20, cells were incubated with the
anti-FLAG M2 antibody 1:200; Kodak, New Haven,
.CT, USA and then for 1 h with an FITC-labeled
Donkey-anti-mouse secondary antibody 1:500; Jack-
.son, Baltimore, MD, USA . Preparations were
 .mounted in FA fluid Difco, Grayson, USA and
viewed under a Nikon epifluorescence microscope.
2.6. Northern blot analysis
Total cellular RNA was isolated from cultured
w xcells or organs essentially as described 21 . 10 mg of
total RNA was fractionated on agaroserformal-
dehyde gel, transferred to a Hybond N membrane
 .Amersham, Little Chalfont, UK by capillary action
in 20 times SSC for 16 h and immobilized by UV
cross-linking Autocrosslink on Appligene cross
.linker, Pleasanton, USA . The filters were pre-hy-
bridized for 6 h in a solution containing 50% for-
mamide, 5=SSPE 0.18 M NaCl, 10 mM sodium
.phosphate, pH 7.7, 1 mM EDTA , 5=Denhart’s,
0.5% SDS, and 100 mgrml denatured salmon sperm
DNA. RNA bound to the membranes was hybridized
with 32P-labeled cDNA probes corresponding to the
coding region of a GT isoform 1, to the porcine1,3
b-actin or to 28S RNA. Hybridization was carried out
overnight at 428C in pre-hybridization solution con-
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taining 106 cpmrml of probe. The filters were washed
twice in 2=SSPE, 0.5% SDS at room temperature
for 15 min, and three times in 0.5=SSPE, 0.5% SDS
at 658C for 15 min. Hybridization was visualized and
signals quantified with a Phosphorimager Molecular
.Dynamics, Sunnyvale, USA . Signals were standard-
ized for variations in the amount and quality of RNA
using b-actin mRNA or 28S RNA as internal con-
trols, detected after de-hybridization 15 min at 908C
.in 10 mM tris, 1 mM EDTA and re-hybridization of
the same filters.
2.7. RNase protection assay
RNase protection assays were performed as de-
w xscribed 22 . Two RNA probes, complementary to
exons 5 and 6 and to exons 4 and 7 respectively,
were prepared as follows: 2 EcoRI-SpeI fragments,
corresponding to nucleotides y7–266 of clone
a GTiso1, and to nucleotides y7–174 of clone
 .a GTiso4 Fig. 1 , were subcloned into the EcoRI-
SpeI sites of pKS plasmids. Using the T7 RNA
32 .polymerase and P dUTP, the antisense RNA probes
were synthesized. Plasmid DNA template was di-
gested with DNAse I, and 500 000 cpm of each probe
was hybridized for 16 h to 10 mg of total RNA from
porcine organs or cells in 30 ml hybridization buffer
containing 80% formamide, at 508C. Control samples
contained 10 mg of yeast tRNA. Hybridization mix-
tures were diluted to 400 ml prior to the addition of 5
mgrml Rnase A and 10 Urml Rnase T1. After 1 h at
308C, 50 mg proteinase K and 0.5% SDS were
added. The mixture was then phenolrchloroform ex-
tracted and ethanol-precipitated. The digestion prod-
ucts were analyzed on 6% polyacrylamide gels. Gels
were exposed for 16 h against Kodak AR films at
y808C.
3. Results
3.1. Cloning of four a GT isoforms1,3
A porcine cDNA expression library constructed
w xusing LLC-PK1 RNA 23 was screened by hy-
bridization with a probe corresponding to the 5X-end
of the coding sequence, as described in Section 2. A
cDNA clone, pcDNA-a GT, with the coding region
corresponding to an already described porcine a GT1,3
w x X20 was isolated. It contains a 770 bp long 3 -un-
translated region, a 1080 bp coding region containing
the porcine homologs of what have been defined in
w xthe mouse as exons 4, and 6–9 12 , and a 150 bp
5X-untranslated region. Using primers flanking exons
Fig. 1. Sequence analysis of pig a GT isoform transcripts aligned with mouse primary transcript map. cDNAs for isoforms 1, 3, and 41,3
were cloned from PCR-amplified reverse-transcribed mRNA from PAEC, and cDNA for isoform 2 was cloned from a LLC-PK1 library,
 .as described in Section 2. Nucleotide sequence was determined using Sequenase USB , and compared for proofreading with previously
w xpublished sequences corresponding to isoforms 1 and 2 20,24 . Bold numbers at left refer to isoforms 1–4. The first bases of exons 5, 6,
and 7 are numbered on isoform 1 sequence. Italic numbers in sequences 2–4 indicate the number of missing bases in the corresponding
w xspliced exon. Compared with these sequences is the mouse primary transcript map with its 9 exons, as described by Joziasse et al. 12 .
 .  .  .The cytoplasmic tail black box and the transmembrane region vertical lines are encoded by exon 4. The stem region half-tone spans
exons 5 and 6. These exons are alternatively spliced in both the mouse and the pig. The catalytic domain is encoded by exons 7, 8, and 9.
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4 and 7, PCR amplification of PAEC cDNA was
performed. We found amplification products of ap-
proximately 200 bp to 300 bp, suggesting the exis-
tence of additional transcripts. Three different prod-
ucts were cloned, one of them being identical to the
w x sequence reported by Strahan et al. 24 and referred
.to here as isoform 1, Fig. 1 . As compared to isoform
 .2 from clone pcDNA-a GT , it contains an addi-
tional 36 bp segment after nucleotide 80. Another
product, isoform 3, lacks a 63 bp long segment from
nucleotides 117–179. The last product, isoform 4,
lacks both the 36 bp long segment from nucleotide 81
to nucleotide 116, and the 63 bp long segment from
 .nucleotide 117 to nucleotide 179 Fig. 1 . Translation
of the mRNAs that correspond to each of the identi-
fied transcripts predicts the synthesis of four related
forms of the a GT polypeptide of 372, 360, 351,1,3
and 339 amino acids that differ only in the length of
their respective stem regions. The situation described
w xhere is reminiscent of that reported for the mouse 12
in that four different mRNAs are found, containing
both exons 5 and 6, containing exon 5 or exon 6
alone, or lacking both exons 5 and 6. The 36 bp and
63 bp long segments in the pig correspond closely to
exons 5 and 6 in the mouse, except that in the latter
 .exon 6 is 66 bp long instead of 63 in the pig Fig. 1 .
Analysis of the 5X untranslated region in clone
pcDNA-a GT revealed a 106 bp insertion at nu-
 .cleotide y5 data not shown , as compared with
w xpreviously reported pig a GT sequences 20,24 .1,3
This insertion demonstrates that further heterogeneity
within the 5X-untranslated region can occur.
3.2. a GT acti˝ity of the splicing isoforms1,3
The presence or absence of exons 5 and 6 deter-
mines four variations in length in the stem region of
a GT. This region, located inside the Golgi appara-1,3
tus, links the transmembrane signal anchor to the
catalytically active luminal domain. To determine
whether or not the four isoforms defined by alterna-
tive splicing of exons 5 and 6 were catalytically
active, we transduced human HeLa cells with recom-
binant plasmids expressing each of the four pig
a GT isoforms under the control of the CMV pro-1,3
moter. We analyzed the product of this enzyme on
cell surfaces by immunofluorescence, using the IB-4
lectin specifically reacting with Gala residues. The
Gala epitope was detectable on the surface of HeLa
cells transduced with all four isoforms of the enzyme,
 .as evidenced by IB-4 lectin binding Fig. 2 , indicat-
ing that these isoenzymes all possess a-galacto-
syltransferase activity. Expression levels of a GT1,3
mRNAs in HeLa-pig a GT clones were investigated1,3
by Northern blotting and, compared to the level in
resting PAEC, found to be slightly higher in the
clones shown in Fig. 2 containing isoforms 1 and 4
and slighly lower for the clone containing isoforms 2
 .and 3 data not shown .
3.3. Subcellular localization of a GT isoforms1,3
The localization of a GT in the Golgi apparatus1,3
is due to the presence of a signal-anchor domain in
exon 4. Variations in length in the stem region, i.e.,
the presence or absence of exons 5 and 6, may also
w xinfluence retention in the Golgi 9 or expose a
protease-sensitive cleavage site on certain isoforms
w x14,25–27 . To determine whether variations in the
stem region of a GT might modify localization in1,3
the Golgi complex, we analyzed the cellular localiza-
tion of the different isoforms. The four CMV-based
expression vectors described above express the
a GT isoforms with a FLAG tag fused to the1,3
C-terminus, allowing us to detect the protein by
indirect immunofluorescence in transfected HeLa cells
with an anti-FLAG antibody. As observed by fluores-
 .cence microscopy Fig. 2 , the four isoforms are
similarly localized and form a compact juxtanuclear
structure corresponding to that of the Golgi apparatus
w x5 . Surprisingly, while 100% of the cells expressed
the enzyme, as evidenced by the uniform staining
obtained with the IB4 lectin, they did not all show
detectable enzyme with the anti-FLAG antibody. This
may be due either to uneven expression of the en-
zyme associated with a limited sensitivity of the
antibody, or to the reorganisation of the Golgi appara-
tus during the cell cycle, which has been shown in
Hela cells to form discrete clusters dispersed in the
w xcytoplasm 28 .
3.4. Tissue-specific and regulated expression of
a GT isoforms1,3
The Gala Gal epitope resulting from the activity1,3
of a GT is not expressed homogeneously in pig1,3
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Fig. 3. Northern blot analysis of a GT mRNA. A. Total RNA1,3
 .  .  .10mg from resting PAEC 1 , TNFa-stimulated PAEC 2 ,
 .TNFa qcycloheximide-stimulated PAEC 3 , cycloheximide-
 .  .  .  .  .stimulated PAEC 4 , heart h , thymus t , lung lu , ovary o ,
 .  .  .kidney k , spleen s , and liver li were blotted and hybridized
sequentially with a GT, and b-actin or 28S RNA probes. The1,3
membrane was exposed for 16 h to a PhosphorImager Molecular
.  .Dynamics . B : The magnitude of the signals corresponding to
the a GT and internal control transcripts were quantified using1,3
 .the IPLab Gel program Signal Analytics, Vienna, VA, USA .
Signal counts deduced from background were standardized ac-
cording to the signals given by b-actin hybridization for endothe-
lial cells, or by signals given by 28S RNA hybridization for
tissues. a GT transcripts from tissues were standardized using1,3
28S RNA because of the weak expression of b-actin in the heart.
For endothelial cells, the expression level in the TNFa-stimulated
 .cells was arbitrarily taken as 10 U left panel , and for the organs,
the expression level in the spleen was arbitrarily taken as 10 U
 .right panel .
w xtissues 29 . To investigate these variations at enzyme
level, we analyzed the steady state level of a GT1,3
transcripts by Northern blotting and the distribution
of transcript isoforms by RNAse protection assay.
 .Northern blot analysis Fig. 3 showed expression in
all tissues investigated, but with striking differences
between them. The kidneys contain levels about 50%
of those found in the spleen, the thymus 40%, and the
heart and ovaries 20–25%. The lungs and liver con-
Fig. 4. Diagram of a GT transcript regions protected by probes1,3
used in RNAse protection assays. Diagram of the sequences in
four a GT transcript isoforms that hybridize to the antisense1,3
 .RNA probes 1 and 4 bold lines . Nucleotide and exon numbers
on probes refer to sequence 1 in Fig. 1. Predicted lengths in bp of
protected probe fragments are indicated on the corresponding
isoform fragments that hybridize to them. Gaps in the lines
representing isoforms 2, 3, and 4 on top panel have been intro-
duced to align with probe 1.
tain levels less than 10% of those in the spleen.
Stimulation of endothelial cells with inflammatory
cytokines induces the up-regulation or synthesis of
many genes, including adhesion molecules and
molecules related to inflammation and coagulation.
Up-regulation of a GT upon such activation has, to1,3
our knowledge, not been reported in endothelial cells
hitherto. Using PAEC stimulated for 6 hours with
100 Urml of human TNFa , we observed a two-fold
increase in the overall level of a GT mRNA. The1,3
relevance of this increase in terms of the number of
Gala -Gal epitopes on the endothelial cells is being1,3
investigated independently. Incubation of PAEC in
the presence of cycloheximide also increases the
level of a GT mRNA, perhaps as a result of the1,3
messenger being stabilized. Surprisingly, TNFaq
cycloheximide stimulation resulted, not in an in-
creased level of a GT mRNA, but rather in a1,3
 .moderate decrease of about 30% . This effect could
be related to the finding that cycloheximide facilitates
TNFa-mediated apoptosis, resulting in the down-
w xmodulation of some antigens 30 .
Fig. 2. Enzyme activity and localization of the four a GT-Flag isoforms in the Golgi apparatus of HeLa cells by immunofluorescence1,3
microscopy. HeLa cells stably transfected with CMV-based expression plasmids containing the four a GT isoforms were grown on1,3
coverslips and fixed with 3% paraformaldehyde. Membrane Gala epitopes, testifying to a GT activity, were detected with FITC-IB-41,3
lectin. For cellular localisation, cells were permeabilized and FLAG peptides detected with anti-FLAG M2 antibody followed by
incubation with FITC-conjugated donkey anti-mouse IgG second antibody. No cell surface immunofluorescence was detected for any of
these isoforms.
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The expression pattern of a GT transcript iso-1,3
forms in pig tissues was analyzed by RNAse protec-
tion assay. Two antisense RNA probes were used to
 .detect the four identified isoforms Fig. 4 . Isoform 1
mRNA transcript hybridizes to and protects a 273 bp
fragment on probe 1 corresponding to a sequence
from nucleotides y7 to 266 on the transcript
nucleotide numbers refer to the sequence presented
.in Fig. 1, isoform 1 . Protection of probe 1 by
isoform 2 mRNA predicts a 87 bp fragment from
nucleotides y7 to 80, and a larger 150 bp fragment
from nucleotides 117 to 266. Protection of probe 1 by
isoform 3 mRNA predicts a 123 bp fragment from
nucleotides y7 to 116 and a smaller 87 bp fragment
from nucleotides 180 to 266. Protection of probe 1 by
a GT isoform 4 mRNA gives two fragments of 871,3
bp, from nucleotides y7 to 80 and from nucleotides
180 to 266. The second probe, probe 4, is a 174 bp
antisense RNA fragment corresponding to isoform 4.
It is entirely protected by isoform 4 mRNA, and
gives rise to two 87 bp fragments with isoforms 1, 2,
and 3. Bands below 123 bp have been excluded from
Fig. 5, so that the probe fragments protected by
isoform 1, 2, and 3 mRNA are of 273, 150, and 123
bp respectively. Probe 4 protected by isoform 4
 .mRNA gives a band of 174 bp. The data Fig. 5
show that four transcripts of the predicted size can be
found in pig mRNA. Transcripts corresponding to
isoform 3, however, are barely detectable. The tran-
script patterns differ from one tissue to another:
Kidney contains isoform 3 alone, and the ovaries
isoform 4 alone. Heart, lungs and spleen contain
isoforms 1 and 2, and liver isoforms 2 and 4. Resting
endothelial cells express isoforms 1, 2, and 4. In the
thymus, all four isoforms are found.
In endothelial cells, TNFa stimulation, which up-
regulates the steady state level of a GT as observed1,3
by Northern blotting, does not modify the isoform
 .patterns Fig. 5, lanes 1q3 . The reduction of the
overall a GT mRNA level after TNFa q1,3
 .  .  .Fig. 5. RNAse protection analysis of a GT mRNA. Total RNA 10mg from resting PAEC 1,4 , TNFa-stimulated PAEC 3 ,1,3
 .  .  .  .  .  .  .  .TNFaqcycloheximide-stimulated PAEC 2,5 , heart h , thymus t , lung lu , ovary o , kidney k , spleen s , and liver li were
subjected to RNAse protection assay as described in Section 2. The equal loading of RNA on each well was checked by parallel loading
on a formaldehyde gel stained by ethidium bromide. Product size was estimated on the gels with a sequencing ladder and positions and
size of the expected signals are indicated on the left of each panel, in base pairs. Using probe 1, a GT isoforms 1, 2, and 3 give bands1,3
of 273, 150, and 123 bp, respectively. Using probe 4, a GT isoform 4 gives a band of 174 bp.1,3
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cycloheximide stimulation affects all three isoforms
 .present in these cells isoforms 1, 2, and 4 . Such a
reduction has been observed in two independent ex-
 .periments Fig. 5, lanes 1q2 and 4q5 . In the first
 .instance lanes 1q2 , however, the reduction of
isoform 4 is less pronounced than in the second
 .lanes 4q5 .
4. Discussion
That a single gene may generate a family of
differing transcripts has been reported for the expres-
w xsion of a large number of genes 31–35 , including
the glycosyltransferases. For instance, alternative
transcriptional initiation in b -galactosyltransferase1,4
results in mRNAs that putatively use one of two
w xin-frame AUGs for translational initiation 36 . The
two forms of this enzyme, differing in the 13 amino
acids at the N-terminus, are either located in the
Golgi apparatus or are targeted to the plasma mem-
w xbrane 10,11 . In a -sialyltransferase, alternative ex-2,6
pression of the 5X-untranslated region has been impli-
w xcated in the regulation of translation 13 , and a
shorter, soluble form of that enzyme secreted in the
liver results from proteolytic cleavage of the catalytic
w xdomain from its membrane anchor 14,15 . For mouse
w xa GT, Joziasse et al. 12 have demonstrated how1,3
alternative splicing of exons 5 and 6 results in the
production of four transcripts. In addition to this
variability, it is well known that expression of some
glycosyltransferases is tissue-specific, including b-
w xgalactoside a -sialyltransferase 13,37 , and in par-2,6
ticular a GT in pigs, where the Gala Gal epitope1,3 1,3
has been detected mainly in the kidney and the
endothelium but not, for example, in the liver or in
w xthe intestine 29 .
In order to investigate the relative expression of
a GT and of its different transcripts in porcine1,3
tissues, we performed Northern blot analyses and
RNAse protection assays using probes hybridizing to
the nucleotide segments coding for the stem region, a
polypeptide segment of approximately 50 amino acids
that links the luminal catalytic domain to the trans-
membrane domain. We present evidence for the ex-
pression of at least four a GT transcripts in the pig,1,3
the four isoforms differing from each other in the
length of their stem region. We found varying
stretches in this region of nucleotide segments corre-
sponding to 12 and 21 amino acids. The points of
divergence between the four a GT transcripts are1,3
most probably intron-exon boundaries as demon-
w xstrated in the mouse 12 , because of the nearly
perfect conservation of the sizes of the alternatively
displayed segments. We found a single transcript in
the kidney that contained the 12 amino acid segment
 .isoform 3 , and in the ovary, where no spliced
 .segment is displayed isoform 4 . Other tissues tested
contain up to four different a GT transcripts with1,3
alternative display of the segments of 12 and 21
amino acids. Apparently protected fragments of ap-
proximately 220 and 170 bp in the thymus and the
 .kidneys Fig. 5 are unlikely to represent additional
isoforms, as transcripts of corresponding sizes have
 .not been detected by PCR analysis data not shown .
Alternatively, they may represent background hy-
bridization of the probe or partial protection against
RNAse in the assay. These data demonstrate that
there is a tissue specific pattern of isoforms in porcine
a GT transcripts, in addition to the differences in1,3
overall levels of expression between tissues as evi-
denced by Northern blot analysis.
There are several instances in which the level of
glycosyltransferase gene expression appears to be
regulated: the expression of b-galactoside a -2,6
sialyltransferase is up-regulated by cytokines, gluco-
w xcorticoids, or by ras transformation 38–40 , and the
level and structure of the b -galactosyltransferase1,4
w xmRNA are cell-cycle dependent 41,42 . With regard
to a GT, it has been observed that enzyme activity1,3
w xincreases in macrophages upon activation 43 and
that the level of transcription is up-regulated by
retinoic acic in the F9 mouse teratocarcinoma cell
w xline 44 . The observation made here in endothelial
cells is to some extent similar: TNFa stimulation
results in a two-fold increase in the steady state level
of a GT. However, such stimulation in the pres-1,3
ence of cycloheximide reduced the level of a GT1,3
mRNA, an effect not seen when cycloheximide alone
is used. This is surprising, as many molecules in
endothelial cells known to be regulated upon activa-
tion are up-regulated by TNFaqcycloheximide. The
effect of TNFaqcycloheximide on the level of
a GT transcripts is also rendered clearly visible by1,3
 .RNAse protection assay Fig. 5 . The precise mecha-
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nism by which a GT gene expression level is regu-1,3
lated was not elucidated. Regulation at the level of
gene transcription has recently been demonstrated
w x44 . In terms of the pattern of a GT isoforms1,3
expressed in endothelial cells upon activation, no
obvious variation could be observed, suggesting that
no regulation takes place in the splicing of exons 5
and 6, at least in the period shortly after TNFa
stimulation.
As well as the variation in the levels of a GT1,3
transcripts between tissues, there appears to be a
species-dependent expression of a GT in addition1,3
.to the absence of this enzyme in apes and man , as
only a single a GT transcript was observed in1,3
w xbovine thymus and MDBK cells 12 , whereas at least
w xfour transcripts are found in the mouse 12 and in the
 .pig this study .
It has been established that galactosyltransferase is
w xlocalized in the trans Golgi 5 and that truncations in
the stem region maintains to some extent the catalytic
w xactivity in vitro 45 , but whether isoenzymes display-
ing alternatively exons 5 and 6 are co-localized to the
Golgi was not documented. Although precise defini-
tion of the a GT isoform-containing subcompart-1,3
ments would necessitate a study using immunoelec-
tronmicroscopy, our results obtained using light mi-
croscopy in transfected HeLa cells show that all four
isoforms of a GT are found primarily in the same1,3
compartment and that variations in the intra-Golgi
stem region do not affect overall galactosyltrans-
ferase activity. These observations imply that the
different expression patterns of the isoforms seen in
different tissues may not result in modification of
enzyme localization or activity, except insofar as the
overall expression level varies. Variations in length in
the stem region, however, may modify susceptibility
to proteolytic cleavage, resulting in the production of
a soluble, active form of the enzyme lacking an
N-terminal Golgi retention peptide. Such proteolytic
activity may itself be regulated, for example by cell
activation or by tissue-specific expression.
The biological significance of the variation in
a GT expression between tissues is unclear. Be-1,3
cause the a GT activity in some cells competes1,3
w xwith other glycosyltransferases 46,47 and results in
w xthe masking of other glycosylated antigens 44 , regu-
lation of a GT expression may well modulate1,3
mechanisms, such as cell to cell interaction, in which
carbohydrate epitopes other than Gala Gal alone1,3
are involved.
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